Mission: The Patients Equal Access Coalition (PEAC) is a patient focused coalition of
organizations representing patients, health care professionals, care centers, and industry
collaboratively joined together to ensure that cancer patients have equality of access (and
equality of insurance coverage) to all approved anticancer regimens including, but not
limited to oral and intravenous drugs, injections, surgery, radiation, transplantation, etc.
PEAC believes that every cancer patient should have access to the anticancer regimens
recommended by their physicians and should not suffer from cost discrimination based on
the type of therapy provided or the mechanism of delivery.
Area of Focus: Equal reimbursement parity for anticancer regimens regardless of delivery
method including, but not limited to oral and intravenous drugs, injections, surgery,
radiation, transplantation, etc.
Goals of the Coalition:
1. Ensure that all major stakeholders (patients, non-cancer orgs, providers, industry,
etc.) are represented in some way.
2. Ensure that access to anticancer regimens regardless of delivery method is
maintained and patients don't have to forgo taking their medication because of the
expense.
3. Educate policymakers at all levels about the impact of disparities in anticancer
regimens reimbursement
4. Raise visibility of this issue in Congress through activities such as Congressional
briefings and hearings.
5. Ensure that a federal bill is enacted as a "floor" so that more patient friendly state
laws are not preempted.
6. Ensure that federal legislation does not contain loopholes with unintended
consequences for the patient. Federal legislation should include provisions such as:
a. A patient's out of pocket costs related to coverage for orally administered
chemotherapy shall be on a basis no less favorable than current coverage
provided for intravenously administered or injected chemotherapy under the
policy.
b. A health insurer cannot achieve compliance with this section by imposing an
increase in patient out of pocket costs with respect to intravenously
administered or injected chemotherapy agents covered under the policy on
the effective date of the legislation.
c. Nothing herein shall be interpreted to prohibit a health insurer from
requiring prior authorization or imposing other appropriate utilization
controls in approving coverage for any chemotherapy.
7. Ensure that progress continues at the state level on these issues.

---